IBSA Group in the news
Global pharmaceutical, diverse products
Tamtam found 20 recent articles about IBSA Group.
- IBSA USA Announces FDA Approval of VYBRIQUE™, the First and Only Oral Film to Treat Men with Erectile Dysfunction
IBSA USA's VYBRIQUE™, the first FDA-approved sildenafil oral film for erectile dysfunction, offers a discreet, easy-to-use treatment option for men.
- IBSA USA Announces FDA Approval of VYBRIQUE™, the First and Only Oral Film to Treat Men with Erectil
IBSA USA's VYBRIQUE™, the first FDA-approved oral sildenafil film for erectile dysfunction, will launch in the US in March 2026 with convenient dosing and home delivery.
- Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA
Acertis Pharmaceuticals licensed U.S. rights to Licart®, an FDA-approved once-daily topical NSAID patch from IBSA, enhancing its pain management portfolio.
- Acertis Pharmaceuticals Licenses U.S. Commercial Rights to Licart® from IBSA
Acertis Pharmaceuticals acquired U.S. rights from IBSA for Licart®, an innovative once-daily topical NSAID patch for acute pain relief.
- New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement That’s Gentle on the Stomach and Easy to Take
IBSA introduced a fast-dissolving iron and folic acid film supplement that minimizes digestive discomfort and is easy to take without water.
- New Way to Take Iron: IBSA Launches Innovative Orally Dissolving Film Supplement That’s Gentle on the Stomach and Easy to Take
IBSA introduced a fast-dissolving iron and folic acid film supplement that minimizes digestive side effects and is easy to take without water.
- Universal Unilink Acquires IBSA To Expand Healthcare Print & Promo Capabilities
Universal Unilink acquired IBSA to access healthcare print contracts and expand promotional product offerings to its members.
- Edition of the Fellowships Promoted by IBSA Foundation for Scientific Research
IBSA Foundation awarded fellowships to young researchers for innovative projects in aging, endocrinology, and other fields, highlighting its commitment to supporting scientific progress globally.
- Die sechs Gewinnerprojekte der 12. Ausgabe der Stipendien von IBSA Foundation wurden bekannt gegeben, und die Ausschreibung für 2025 ist nun eröffnet
IBSA Foundation awarded six €32,000 fellowships to young researchers in five medical fields, received a record number of applications in 2024, and opened the 2025 call including a new prize for projects in developing countries.
- Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open
IBSA Foundation awarded fellowships to young researchers in pharmaceutical-related fields and opened the 2025 call, supporting innovation and social responsibility.
- The Six Winning Projects of the 12 th Edition of the IBSA Foundation Fellowships have been Awarded and the 2025 Call is Now Open
IBSA Foundation awarded fellowships to young researchers in key medical fields and opened the 2025 call, supporting innovation and social responsibility in pharmaceutical research.
- Arturo Licenziati appointed Honorary Member of USI
Arturo Licenziati, CEO of IBSA Group, was honored by USI for his significant support to biomedical education and research through IBSA Foundation's scholarships and collaborations.
- IBSA celebrates 40 years of Leadership and Innovation
IBSA marks 40 years of growth and innovation under CEO Arturo Licenziati, evolving from a small Swiss pharma firm to a global company focused on patient-centered pharmaceutical technologies.
- 40-year milestone for Swiss pharma group
IBSA has grown from a small Swiss pharma firm to a global group over 40 years under CEO Licenziati, focusing on innovative drug delivery and unmet therapeutic needs.
- IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people
IBSA Group marks 40 years of leadership under CEO Licenziati, growing from a small Swiss lab to a global pharmaceutical innovator with over 2,300 employees.
- IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people
IBSA Group marks 40 years of leadership under Arturo Licenziati, growing from a small Swiss pharmaceutical lab into a global multinational focused on innovative drug development.
- IBSA feiert 40-jähriges Bestehen: „Arzneimittel in ihrer besten Form” – eine Erfolgsgeschichte, die Innovation mit der Philosophie „Der Mensch im Mittelpunkt” verbindet
IBSA Group marks 40 years of leadership under CEO Licenziati, evolving from a small Swiss pharma lab into a global innovator with 2,300+ employees and presence in over 90 countries.
- IBSA celebrates 40 years of history: “Drugs in the best form” – a success story that combines innovation with a focus on people
IBSA Group has grown from a small Swiss pharmaceutical lab into a global company with over 2,300 employees, focusing on innovative drug forms and global expansion under CEO Arturo Licenziati.
- Jacopo Crespi, Communication Specialist, IBSA
Jacopo Crespi, a USI graduate, works in institutional communication at IBSA Group, managing digital content and events for their scientific research foundation.
- Buonasera Düsseldorf: Marion Bock, Geschäftsführerin bei "IBSA Pharma"
Marion Bock leads IBSA Pharma's new German branch, highlighting its Italian roots and bilingual work environment.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like IBSA Group?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies